421 related articles for article (PubMed ID: 21544705)
41. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.
Calcagno A; Simiele M; Alberione MC; Bracchi M; Marinaro L; Ecclesia S; Di Perri G; D'Avolio A; Bonora S
Clin Infect Dis; 2015 Jan; 60(2):311-7. PubMed ID: 25281609
[TBL] [Abstract][Full Text] [Related]
42. Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms.
Kugathasan R; Collier DA; Haddow LJ; El Bouzidi K; Edwards SG; Cartledge JD; Miller RF; Gupta RK
Clin Infect Dis; 2017 Apr; 64(8):1059-1065. PubMed ID: 28329096
[TBL] [Abstract][Full Text] [Related]
43. Regionally Specific Brain Volumetric and Cortical Thickness Changes in HIV-Infected Patients in the HAART Era.
Sanford R; Fernandez Cruz AL; Scott SC; Mayo NE; Fellows LK; Ances BM; Collins DL
J Acquir Immune Defic Syndr; 2017 Apr; 74(5):563-570. PubMed ID: 28129254
[TBL] [Abstract][Full Text] [Related]
44. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
[TBL] [Abstract][Full Text] [Related]
45. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.
Idoko J; Meloni S; Muazu M; Nimzing L; Badung B; Hawkins C; Sankalé JL; Ekong E; Murphy R; Kanki P; Thio CL
Clin Infect Dis; 2009 Oct; 49(8):1268-73. PubMed ID: 19772386
[TBL] [Abstract][Full Text] [Related]
46. The impact of human immune deficiency virus and hepatitis C coinfection on white matter microstructural integrity.
Heaps-Woodruff JM; Wright PW; Ances BM; Clifford D; Paul RH
J Neurovirol; 2016 Jun; 22(3):389-99. PubMed ID: 26689572
[TBL] [Abstract][Full Text] [Related]
47. Longitudinal assessment of subcortical gray matter volume, cortical thickness, and white matter integrity in HIV-positive patients.
Corrêa DG; Zimmermann N; Tukamoto G; Doring T; Ventura N; Leite SC; Cabral RF; Fonseca RP; Bahia PR; Gasparetto EL
J Magn Reson Imaging; 2016 Nov; 44(5):1262-1269. PubMed ID: 27079832
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
[TBL] [Abstract][Full Text] [Related]
49. Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment.
Hua X; Boyle CP; Harezlak J; Tate DF; Yiannoutsos CT; Cohen R; Schifitto G; Gongvatana A; Zhong J; Zhu T; Taylor MJ; Campbell TB; Daar ES; Alger JR; Singer E; Buchthal S; Toga AW; Navia B; Thompson PM;
Neuroimage Clin; 2013; 3():132-42. PubMed ID: 24179857
[TBL] [Abstract][Full Text] [Related]
50. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease.
Letendre SL; Cherner M; Ellis RJ; Marquie-Beck J; Gragg B; Marcotte T; Heaton RK; McCutchan JA; Grant I;
AIDS; 2005 Oct; 19 Suppl 3():S72-8. PubMed ID: 16251831
[TBL] [Abstract][Full Text] [Related]
51. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
[TBL] [Abstract][Full Text] [Related]
52. Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat.
Choi JY; Hightower GK; Wong JK; Heaton R; Woods S; Grant I; Marcotte TD; Ellis RJ; Letendre SL; Collier AC; Marra CM; Clifford DB; Gelman BB; McArthur JC; Morgello S; Simpson DM; McCutchan JA; Richman DD; Smith DM;
J Neurovirol; 2012 Apr; 18(2):81-90. PubMed ID: 22528397
[TBL] [Abstract][Full Text] [Related]
53. Cognitive disorders in HIV-infected patients: are they HIV-related?
Bonnet F; Amieva H; Marquant F; Bernard C; Bruyand M; Dauchy FA; Mercié P; Greib C; Richert L; Neau D; Catheline G; Dehail P; Dabis F; Morlat P; Dartigues JF; Chêne G;
AIDS; 2013 Jan; 27(3):391-400. PubMed ID: 23079813
[TBL] [Abstract][Full Text] [Related]
54. Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study.
Rauch A; Gaudieri S; Evison J; Nolan D; Cavassini M; Weber R; James I; Furrer H;
Antivir Ther; 2008; 13(3):455-60. PubMed ID: 18572759
[TBL] [Abstract][Full Text] [Related]
55. HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter.
Keltner JR; Fennema-Notestine C; Vaida F; Wang D; Franklin DR; Dworkin RH; Sanders C; McCutchan JA; Archibald SL; Miller DJ; Kesidis G; Cushman C; Kim SM; Abramson I; Taylor MJ; Theilmann RJ; Julaton MD; Notestine RJ; Corkran S; Cherner M; Duarte NA; Alexander T; Robinson-Papp J; Gelman BB; Simpson DM; Collier AC; Marra CM; Morgello S; Brown G; Grant I; Atkinson JH; Jernigan TL; Ellis RJ;
J Neurovirol; 2014 Jun; 20(3):209-18. PubMed ID: 24549970
[TBL] [Abstract][Full Text] [Related]
56. Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.
Gras L; de Wolf F; Smit C; Prins M; van der Meer JT; Vanhommerig JW; Zwinderman AH; Schinkel J; Geskus RB;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):536-42. PubMed ID: 25559595
[TBL] [Abstract][Full Text] [Related]
57. Cocaine dependence does not contribute substantially to white matter abnormalities in HIV infection.
Cordero DM; Towe SL; Chen NK; Robertson KR; Madden DJ; Huettel SA; Meade CS
J Neurovirol; 2017 Jun; 23(3):441-450. PubMed ID: 28251596
[TBL] [Abstract][Full Text] [Related]
58. Association of Immunosuppression and Viral Load With Subcortical Brain Volume in an International Sample of People Living With HIV.
Nir TM; Fouche JP; Ananworanich J; Ances BM; Boban J; Brew BJ; Chaganti JR; Chang L; Ching CRK; Cysique LA; Ernst T; Faskowitz J; Gupta V; Harezlak J; Heaps-Woodruff JM; Hinkin CH; Hoare J; Joska JA; Kallianpur KJ; Kuhn T; Lam HY; Law M; Lebrun-Frénay C; Levine AJ; Mondot L; Nakamoto BK; Navia BA; Pennec X; Porges EC; Salminen LE; Shikuma CM; Surento W; Thames AD; Valcour V; Vassallo M; Woods AJ; Thompson PM; Cohen RA; Paul R; Stein DJ; Jahanshad N
JAMA Netw Open; 2021 Jan; 4(1):e2031190. PubMed ID: 33449093
[TBL] [Abstract][Full Text] [Related]
59. CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration.
Abdulle S; Mellgren A; Brew BJ; Cinque P; Hagberg L; Price RW; Rosengren L; Gisslén M
J Neurol; 2007 Aug; 254(8):1026-32. PubMed ID: 17420923
[TBL] [Abstract][Full Text] [Related]
60. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.
Sinclair E; Ronquillo R; Lollo N; Deeks SG; Hunt P; Yiannoutsos CT; Spudich S; Price RW
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):544-52. PubMed ID: 18362693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
